Allena Pharmaceuticals (ALNA) Downgraded to “Sell” at Zacks Investment Research

Allena Pharmaceuticals (NASDAQ:ALNA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

According to Zacks, “Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. “

Several other research firms have also issued reports on ALNA. Credit Suisse Group started coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They issued an “outperform” rating and a $22.00 price target on the stock. Wedbush started coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They issued an “outperform” rating and a $30.00 price target on the stock. ValuEngine upgraded shares of Allena Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Cowen started coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They issued an “outperform” rating on the stock. Finally, Jefferies Group started coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They issued a “buy” rating and a $22.00 price target on the stock. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Allena Pharmaceuticals currently has an average rating of “Hold” and an average target price of $24.67.

Allena Pharmaceuticals (NASDAQ ALNA) traded down $0.36 during trading on Tuesday, reaching $6.55. 65,000 shares of the company’s stock traded hands, compared to its average volume of 53,197. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of -0.09. Allena Pharmaceuticals has a 12-month low of $6.25 and a 12-month high of $15.40.

Allena Pharmaceuticals (NASDAQ:ALNA) last posted its quarterly earnings results on Thursday, December 14th. The company reported ($3.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($3.11). sell-side analysts predict that Allena Pharmaceuticals will post -0.89 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. Sphera Funds Management LTD. acquired a new position in Allena Pharmaceuticals in the 4th quarter worth approximately $3,270,000. BlackRock Inc. acquired a new position in Allena Pharmaceuticals in the 4th quarter worth approximately $2,281,000. Bank of New York Mellon Corp acquired a new position in Allena Pharmaceuticals in the 4th quarter worth approximately $102,000. Finally, Dean Capital Investments Management LLC acquired a new position in Allena Pharmaceuticals in the 4th quarter worth approximately $116,000. Hedge funds and other institutional investors own 0.07% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Allena Pharmaceuticals (ALNA) Downgraded to “Sell” at Zacks Investment Research” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/13/allena-pharmaceuticals-alna-downgraded-to-sell-at-zacks-investment-research.html.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply